The Christie

Running trials

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer

  NCT07831902· Phase 3· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Source

• Not yet recruiting

  A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.

  NCT07268339· Phase 3· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Source

• Active, not recruiting

  Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

  NCT05093231· Phase 2· Source

• Recruiting

  A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

  NCT06789172· Phase 1· Source

• Recruiting

  Study of STP938 (Dencatistat) in Advanced Solid Tumours

  NCT06297525· Phase 1· Source

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  NCT06004245· Phase 1· Source

• Recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

  NCT05800665· Phase 1· Source

• Active, not recruiting

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Phase 3· Source

• Recruiting

  Methods of T Cell Depletion Trial (MoTD)

  NCT04888741· Phase 2· Source

• Active, not recruiting

  ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

  NCT04065269· Phase 2· Source

• Recruiting

  Serial Tumour Biopsies and Blood Biomarkers in Melanoma

  NCT04493723· Source

• Recruiting

  Renal Adjuvant MultiPle Arm Randomised Trial

  NCT03288532· Phase 3· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· Source

• Recruiting

  Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

  NCT03150576· Phase 2/3· Source

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers4 recruiting
• Colorectal cancer3 recruiting
• Gastric and esophageal cancer3 recruiting
• Lung cancer3 recruiting
• Multiple myeloma2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Source

• Completed

  CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

  NCT04145349· Phase 1/2· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

  NCT03767335· Phase 1· Source

• Completed

  Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

  NCT03117933· Phase 2· Source